Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Usage Information

Endothelial Cell Glycogen Synthase Kinase 3β Promotes Lipotoxic Endotheliopathy and Liver Inflammation in MASH
Akitoshi Sano, Qianqian Guo, Khaled Warasnhe, Chady Meroueh, Nantawat Satthawiwat, Asma Hamdi, Ghefar Hmaydoosh, Xin Dai, Usman Yaqoob, Kevin D. Pavelko, Charlene Miciano, Tatiana Kisseleva, Zeba Firdaus, Patrick P. Starlinger, David Pereyra, Enis Kostallari, Petra Hirsova, Davide Povero, Samar H. Ibrahim
Akitoshi Sano, Qianqian Guo, Khaled Warasnhe, Chady Meroueh, Nantawat Satthawiwat, Asma Hamdi, Ghefar Hmaydoosh, Xin Dai, Usman Yaqoob, Kevin D. Pavelko, Charlene Miciano, Tatiana Kisseleva, Zeba Firdaus, Patrick P. Starlinger, David Pereyra, Enis Kostallari, Petra Hirsova, Davide Povero, Samar H. Ibrahim
View: Text | PDF
Research In-Press Preview Hepatology Vascular biology

Endothelial Cell Glycogen Synthase Kinase 3β Promotes Lipotoxic Endotheliopathy and Liver Inflammation in MASH

  • Text
  • PDF
Abstract

In metabolic dysfunction-associated steatohepatitis (MASH), liver sinusoidal endothelial cells (LSECs) acquire a proinflammatory phenotype termed lipotoxic endotheliopathy. We previously identified glycogen synthase kinase 3β (GSK3β) as a central signaling hub in LSECs during MASH. To elucidate the molecular mechanisms and functional outcome of lipotoxicity-induced GSK3β activation in LSECs, we utilized endothelial cell-specific Gsk3β knockout (Gsk3β△End) mice fed MASH-inducing diets. Endothelial Gsk3β deletion significantly reduced markers of lipotoxic endotheliopathy, including adhesion molecules and chemokines, alongside liver injury, inflammation, and fibrosis. Immune profiling via flow cytometry and mass cytometry by time of flight (CyTOF) identified decreased hepatic infiltration of proinflammatory myeloid populations, particularly mature dendritic cells (DCs) in Gsk3β△End mice. In a co-culture system, GSK3β in lipotoxic LSECs promoted DCs maturation. Mechanistically, GSK3 inhibition restored lipotoxicity-induced alterations in LSEC mitochondrial morphology and respiration by regulating AMP-activated protein kinase and dynamin-related protein 1. This rescue suppressed chemokines and adhesion molecules expression, thereby limiting immune cell recruitment. Collectively, under lipotoxic stress, GSK3β amplifies mitochondrial dysfunction and inflammatory signaling in LSECs, enhancing myeloid cell homing and DC maturation. Targeting LSEC GSK3β may therefore represent a promising therapeutic strategy to mitigate LSEC driven fibro inflammatory response in human MASH.

Authors

Akitoshi Sano, Qianqian Guo, Khaled Warasnhe, Chady Meroueh, Nantawat Satthawiwat, Asma Hamdi, Ghefar Hmaydoosh, Xin Dai, Usman Yaqoob, Kevin D. Pavelko, Charlene Miciano, Tatiana Kisseleva, Zeba Firdaus, Patrick P. Starlinger, David Pereyra, Enis Kostallari, Petra Hirsova, Davide Povero, Samar H. Ibrahim

×

Usage data is cumulative from May 2026 through May 2026.

Usage JCI PMC
Text version 210 0
PDF 114 0
Supplemental data 34 0
Citation downloads 27 0
Totals 385 0
Total Views 385

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts